Author Question: Which of the following is not a method to reduce the risk of VAP? a. Nasally intubate whenever ... (Read 27 times)

Sportsfan2111

  • Hero Member
  • *****
  • Posts: 585
Which of the following is not a method to reduce the risk of VAP?
 
  a. Nasally intubate whenever possible.
  b. Provide intermittent nasogastric tube feedings.
  c. Keep patient in a semirecumbent position.
  d. Use heat/moisture exchangers when possi-ble.

Question 2

The main strategy for the management of VAP focuses on which of the following?
 
  a. Pharmacological treatment
  b. Early diagnosis and treatment
  c. Prophylactic antibiotic therapy
  d. Reduction of host-related risk factors



cegalasso

  • Sr. Member
  • ****
  • Posts: 295
Answer to Question 1

ANS: A
Nasal intubation increases the risk of sinusitis, which is associated with ventilator-associated pneumonia. Intermittent nasogastric tube feedings, keeping the patient in a semirecumbent posi-tion, and using heat/moisture exchangers (HME) whenever possible are all methods to decrease the occurrence of VAP.

Answer to Question 2

ANS: B
Although considerable debate has taken place among clinicians regarding the most effective means of diagnosing and treating ventilator-associated pneumonia, it is agreed that successful management of VAP requires early diagnosis and appropriate use of antibiotic therapy to prevent the emergence of multidrug-resistant (MDR) microorganisms.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Nearly 31 million adults in America have a total cholesterol level that is more than 240 mg per dL.

Did you know?

The National Institutes of Health have supported research into acupuncture. This has shown that acupuncture significantly reduced pain associated with osteoarthritis of the knee, when used as a complement to conventional therapies.

Did you know?

In Eastern Europe and Russia, interferon is administered intranasally in varied doses for the common cold and influenza. It is claimed that this treatment can lower the risk of infection by as much as 60–70%.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

Medication errors are more common among seriously ill patients than with those with minor conditions.

For a complete list of videos, visit our video library